Recently, the first anti-HLA-G chimeric antigen receptor (CAR)-T cells targeting HLA-G, which is both a tumour-specific antigen and an immune checkpoint molecule, could specifically target and eliminate both tumour cells and HLA-G+-suppressive cells (Anna et al. 2021). Here, HLA-G is linked to neoplasm.